SEC Form 4 · accession 0001179110-17-012763
ACCELERON PHARMA INC · XLRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ravindra Kumar
Officer — SVP & Chief Scientific Officer
Period of report
Sep 28, 2017
Accepted (ET)
Sep 29, 2017 · 4:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001280600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 28, 2017 | M | 6,761 | $5.28 | A | 96,975 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $5.28 | Sep 28, 2017 | M | 6,761 | D | — | Jun 7, 2022 | Common Stock | 6,761 | 0 | D |
Explanation of responses
- F1The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.